Lilly puts two-thirds of mid-phase cancer pipeline up for sale in major shake up of R&D priorities

Eli Lilly is seeking partners for two-thirds of its mid-phase oncology compounds. The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to mid-stage assets it thinks can become the new standard of care.